Archives

BLOOMINGTON, Minn. -- Hazards of painting, firefighting also examined by international research committee A study by the World Health Organization has found that night shift work increases the risk of cancer in humans. The study found that after prolonged exposure to night shift work, women are at a higher risk to develop breast and colon cancer. Men who work the night shift are more likely to experience prostate cancer. "Shift work that interferes with regular nighttime sleep disrupts circadian rhythms, our body's natural clock," said Dr.

BASEL, Switzerland -- The International Psycho-Oncology Society Introduce a New Global Quality of Life Initiative With the Support of Roche Concerning results from a Europe-wide survey released today during Lung Cancer Awareness Month reveal that one in three lung cancer patients feel that they are not receiving the emotional support they need to manage their life-threatening disease.

SACRAMENTO, Calif. -- Lung cancer is the leading cause of cancer deaths in the U.S. among both men and women. Some of the newest technology available for the early detection and treatment of lung cancer is the new 64-slice the GE LightSpeed VCT scanner available at Sacramento HeartScan. Dennis R. Breen, M.D., F.A.C.C., of the Sacramento Heart and Vascular Institute, which operates Sacramento HeartScan, said that there's a lot of debate surrounding screening of the general population.

People who buy genetic tests from private companies offering to scan their entire genomes for genes linked to diseases such as Alzheimer's or breast cancer are wasting their money, according to a panel of eminent scientists. Several companies have begun offering genome-wide scans of a person's DNA over the internet but potential customers were warned yesterday that the science is still too preliminary to provide any meaningful information.

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, announced that its Phase II clinical protocol to study bavituximab in combination with the chemotherapy drug docetaxel in patients with metastatic breast cancer has been approved by the Drug Agency of the Ministry of Labour, Health and Social Affairs of Georgia. The open label, multi-center safety and efficacy trial is expected to begin enrolling patients by early 2008.

A team of scientists created a new technology intended to detect breast cancer earlier and more precisely through intra-operative 3D imaging to win the 3rd Annual Intel+UC Berkeley Technology Entrepreneurship Challenge (IBTEC) last night. The Navaris Medical entry was judged by a team of venture capitalists from the San Francisco Bay Area. Criteria for the win was the best new technology with the greatest potential for a positive impact on society. Intel awarded the German team $25,000 (see also Breast Cancer).